Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab followed by cisplatin/docetaxel in locally advanced triple-negative breast cancer
ISRCTN50182475Phase 2Completed
- Sponsor
- King Faisal Specialist Hospital and Research Centre
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tocilizumab, cisplatin and docetaxel in triple-negative breast cancer (TNBC), sponsored by King Faisal Specialist Hospital and Research Centre. Primary endpoints: Pathological complete response and Clinical response during treatment. Started Jul 2019; status: completed.
02
Drugs
tocilizumabcisplatindocetaxel
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ISRCTN50182475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN50182475.